159 related articles for article (PubMed ID: 18802666)
1. Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo.
Myers T; Chengedza S; Lightfoot S; Pan Y; Dedmond D; Cole L; Tang Y; Benbrook DM
Invest New Drugs; 2009 Aug; 27(4):304-18. PubMed ID: 18802666
[TBL] [Abstract][Full Text] [Related]
2. Development of flexible-heteroarotinoids for kidney cancer.
Liu T; Masamha CP; Chengedza S; Berlin KD; Lightfoot S; He F; Benbrook DM
Mol Cancer Ther; 2009 May; 8(5):1227-38. PubMed ID: 19417155
[TBL] [Abstract][Full Text] [Related]
3. Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists.
Benbrook DM; Kamelle SA; Guruswamy SB; Lightfoot SA; Rutledge TL; Gould NS; Hannafon BN; Dunn ST; Berlin KD
Invest New Drugs; 2005 Oct; 23(5):417-28. PubMed ID: 16133793
[TBL] [Abstract][Full Text] [Related]
4. CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells.
Lin YD; Chen S; Yue P; Zou W; Benbrook DM; Liu S; Le TC; Berlin KD; Khuri FR; Sun SY
Cancer Res; 2008 Jul; 68(13):5335-44. PubMed ID: 18593935
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of second generation Flex-Het scaffolds against the human ovarian cancer A2780 cell line.
Gnanasekaran KK; Benbrook DM; Nammalwar B; Thavathiru E; Bunce RA; Berlin KD
Eur J Med Chem; 2015; 96():209-17. PubMed ID: 25880346
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of SHetA2 (NSC-721689) analogs against the ovarian cancer cell line A2780.
Nammalwar B; Bunce RA; Berlin KD; Benbrook DM; Toal C
Eur J Med Chem; 2019 May; 170():16-27. PubMed ID: 30878829
[TBL] [Abstract][Full Text] [Related]
7. Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents.
Moxley KM; Chengedza S; Benbrook DM
Gynecol Oncol; 2009 Dec; 115(3):438-42. PubMed ID: 19804900
[TBL] [Abstract][Full Text] [Related]
8. Tetrahydroquinoline units in flexible heteroarotinoids (Flex-Hets) convey anti-cancer properties in A2780 ovarian cancer cells.
Gnanasekaran KK; Pouland T; Bunce RA; Darrell Berlin K; Abuskhuna S; Bhandari D; Mashayekhi M; Zhou DH; Benbrook DM
Bioorg Med Chem; 2020 Jan; 28(1):115244. PubMed ID: 31831296
[TBL] [Abstract][Full Text] [Related]
9. Chemoprevention of colon and small intestinal tumorigenesis in APC(min/+) mice by SHetA2 (NSC721689) without toxicity.
Benbrook DM; Guruswamy S; Wang Y; Sun Z; Mohammed A; Zhang Y; Li Q; Rao CV
Cancer Prev Res (Phila); 2013 Sep; 6(9):908-16. PubMed ID: 23852423
[TBL] [Abstract][Full Text] [Related]
10. Enantiomer of the novel flexible heteroarotinoid, SL-1-09, blocks cell cycle progression in breast cancer cells.
Ginn E; Baek J; Zou H; Fallatah MMJ; Liu S; Sevigny MB; Louie M
Eur J Pharmacol; 2019 Nov; 862():172634. PubMed ID: 31494077
[TBL] [Abstract][Full Text] [Related]
11. The synthetic heteroarotinoid SHetA2 induces apoptosis in squamous carcinoma cells through a receptor-independent and mitochondria-dependent pathway.
Chun KH; Benbrook DM; Berlin KD; Hong WK; Lotan R
Cancer Res; 2003 Jul; 63(13):3826-32. PubMed ID: 12839980
[TBL] [Abstract][Full Text] [Related]
12. Involvement of c-FLIP and survivin down-regulation in flexible heteroarotinoid-induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells.
Lin Y; Liu X; Yue P; Benbrook DM; Berlin KD; Khuri FR; Sun SY
Mol Cancer Ther; 2008 Nov; 7(11):3556-65. PubMed ID: 19001438
[TBL] [Abstract][Full Text] [Related]
13. Novel flexible heteroarotinoid, SL-1-18, promotes ERĪ± degradation to inhibit breast cancer cell growth.
Fallatah MM; Liu S; Sevigny MB; Zou H; Louie MC
Cancer Lett; 2017 Nov; 408():82-91. PubMed ID: 28844711
[TBL] [Abstract][Full Text] [Related]
14. Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53.
Ramraj SK; Elayapillai SP; Pelikan RC; Zhao YD; Isingizwe ZR; Kennedy AL; Lightfoot SA; Benbrook DM
Int J Cancer; 2020 Aug; 147(4):1086-1097. PubMed ID: 31845320
[TBL] [Abstract][Full Text] [Related]
15. SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres.
Benbrook DM; Nammalwar B; Long A; Matsumoto H; Singh A; Bunce RA; Berlin KD
Invest New Drugs; 2014 Jun; 32(3):412-23. PubMed ID: 24254390
[TBL] [Abstract][Full Text] [Related]
16. Activity of oxygen-versus sulfur-containing analogs of the Flex-Het anticancer agent SHetA2.
Watts FM; Pouland T; Bunce RA; Berlin KD; Benbrook DM; Mashayekhi M; Bhandari D; Zhou D
Eur J Med Chem; 2018 Oct; 158():720-732. PubMed ID: 30245396
[TBL] [Abstract][Full Text] [Related]
17. Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice.
Sharma A; Li M; Thavathiru E; Ibrahim M; Garcia-Contreras L; Benbrook DM; Woo S
AAPS J; 2020 Feb; 22(2):51. PubMed ID: 32086622
[TBL] [Abstract][Full Text] [Related]
18. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
Li X; Wang X; Ye H; Peng A; Chen L
Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
[TBL] [Abstract][Full Text] [Related]
19. High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2.
Zhang Y; Hua Y; Benbrook DM; Covey JM; Dai G; Liu Z; Chan KK
Cancer Chemother Pharmacol; 2006 Nov; 58(5):561-9. PubMed ID: 16534614
[TBL] [Abstract][Full Text] [Related]
20. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
